Clinical Trial Update: Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention [Phase 3]

View source ↗

Summary

Phase 3 trial comparing edoxaban to a vitamin K antagonist in atrial fibrillation patients undergoing percutaneous coronary intervention has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Edoxaban (edoxaban)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2020-05-06